Mark Stampehl, MD
Cardiovascular Disease · Montrose, CONPI 1891916219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,905 of the $76,210 with a category attached, or 61.5%. Novartis accounts for 91.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $64,652 and has fallen 98.1% since, to $1,198 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $837.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$70K
- Amgen$4K
- Anumana, Inc.$1K
- Medtronic$926
- Abbott$73
- E.r. Squibb & Sons, L.L.C.$61
- plus $54 from 2 others
Across 6 payments — averaging $7994.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$47K
- Medtronic$693
What the payments were for
- Royalty or licence$1,1752%
- Consulting fees$13,62018%
- Speaking & faculty fees$46,90562%
- Travel & lodging$13,06317%
- Food & beverage$1,4472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $69,938 |
| Amgen | 13 | $3,984 |
| Anumana, Inc. | 1 | $1,175 |
| Medtronic | 3 | $926 |
| Abbott | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Lantheus Medical Imaging, Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,210 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Montrose
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Deborah JalowiecColorado Springs$106K
- Edward GillAurora$96K
- Sameer MehtaDenver$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.